Q3 Earnings Forecast for Pharvaris Issued By HC Wainwright

Pharvaris N.V. (NASDAQ:PHVS) – Analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Pharvaris in a research report issued on Wednesday, October 15th. HC Wainwright analyst P. Trucchio forecasts that the company will earn ($0.69) per share for the quarter. HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Pharvaris’ Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($3.31) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.87) EPS, Q4 2026 earnings at ($0.91) EPS, FY2026 earnings at ($3.42) EPS, FY2027 earnings at ($2.67) EPS, FY2028 earnings at ($0.72) EPS and FY2029 earnings at $2.22 EPS.

A number of other brokerages have also commented on PHVS. Bank of America upgraded Pharvaris from an “underperform” rating to a “neutral” rating and increased their price objective for the company from $16.00 to $27.00 in a research report on Thursday, October 9th. JMP Securities decreased their price objective on Pharvaris from $55.00 to $52.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 13th. Zacks Research upgraded Pharvaris from a “strong sell” rating to a “hold” rating in a research report on Monday, August 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Pharvaris presently has an average rating of “Moderate Buy” and a consensus price target of $37.17.

Pharvaris Price Performance

NASDAQ PHVS opened at $21.86 on Friday. The firm has a market cap of $1.14 billion, a PE ratio of -6.51 and a beta of -2.77. The stock’s 50 day simple moving average is $23.01 and its 200 day simple moving average is $19.31. Pharvaris has a one year low of $11.51 and a one year high of $26.33.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.07).

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new position in shares of Pharvaris in the 2nd quarter valued at $57,000. JPMorgan Chase & Co. lifted its stake in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the period. Legal & General Group Plc lifted its stake in shares of Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares during the period. Palumbo Wealth Management LLC lifted its stake in shares of Pharvaris by 38.0% in the 1st quarter. Palumbo Wealth Management LLC now owns 14,102 shares of the company’s stock valued at $221,000 after purchasing an additional 3,881 shares during the period. Finally, California State Teachers Retirement System raised its stake in Pharvaris by 9.8% during the 2nd quarter. California State Teachers Retirement System now owns 14,048 shares of the company’s stock worth $247,000 after buying an additional 1,257 shares during the period.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.